AFP, which is a valuable in situ and serum marker for the hepatocyte lineage, and also the most important prognostic marker in HCC, showed no significant difference in immunohistochemistry (Figure 7C) or serum levels (rs (E-cadherin) = 0.06, p = 0.42, n = 188; rs (N-cadherin) = −0.04, p = 0.641, n = 188). This evidence concerns the gene CDH2 and hepatocellular carcinoma.